Diabetes med cardio boost

health professional at computer with magnifying glass
A multinational study involving Australian researchers has found more evidence for cardiovascular benefits associated with the newest group of oral medications used to treat type 2 diabetes New research has provided further support for cardiovascular benefits associated with sodium-glucose co-transporter-2 (SGLT2) inhibitors, which are glucose-lowering drugs widely used in the treatment of type 2 diabetes.

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Intern of the Year honoured
Next Leading the pack